MUltiple Sclerosis : T Cell / B Cell Exploration
NCT04231253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90
Last updated 2021-12-02
Summary
This study, an ancillary to ABCD-SEP (NCT03744351), will be interested in more precisely characterizing circulating and infiltrating TH cells in Multiple Sclerosis whether at the transcriptomic level or at the functional level.
Conditions
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Principal Investigators
-
Laure Michel · Rennes University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-02-25
- Primary Completion
- 2021-10-31
- Completion
- 2021-10-31
Countries
- France
Study Locations
More Related Trials
-
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
NCT01442233 ·Status: COMPLETED ·Phase: PHASE3
-
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
NCT04857489 ·Status: UNKNOWN
-
T-Cell Vaccination in Multiple Sclerosis (MS)
NCT00220428 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Dose-finding Study of DC-TAB in Healthy Subjects
NCT02442557 ·Status: COMPLETED ·Phase: PHASE1
-
Therapeutic Adherence of Multiple Sclerosis Patients
NCT04837352 ·Status: RECRUITING
-
Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS)
NCT03796611 ·Status: COMPLETED
-
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
NCT02427776 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631 ·Status: TERMINATED ·Phase: NA
-
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
NCT04530318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
B Cell Differentiation in MS
NCT03744351 ·Status: COMPLETED ·Phase: NA
-
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
NCT06592703 ·Status: RECRUITING ·Phase: PHASE1
-
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation
NCT04674280 ·Status: UNKNOWN
-
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
NCT01863888 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
NCT02418325 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
NCT01065727 ·Status: UNKNOWN ·Phase: NA
-
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
NCT01719159 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis
NCT02035514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
NCT00587691 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients
NCT02117375 ·Status: UNKNOWN ·Phase: NA
-
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
NCT06267781 ·Status: RECRUITING
-
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
NCT00813969 ·Status: COMPLETED ·Phase: PHASE1
-
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
NCT00040482 ·Status: COMPLETED ·Phase: PHASE2